Cortech Inc. (NASDAQ:CRTQ) is ready to begin Phase II trials ofBradycor (CP-0127), a compound designed to fight bradykinin, apeptide that plays a central role in inflammatory processes. Thecompany has completed enrollment at 47 U.S. sites of 500 patientswith systemic inflammatory response syndrome (SIRS) and suspectedsepsis.Cortech's double-blind, placebo-controlled trial will measure the effectof three different doses of Bradycor on mortality, organ failure, andother outcomes. The company will use the APACHE III Sepsis RiskModel to gain a clearer picture of drug response within subgroups ofthe total trial group. This will allow researchers to analyze the effectsof severity of illness, which patients are most likely to benefit from thetreatment, and how to focus additional trials.The SIRS/sepsis trial encompasses studies of the effect of Bradycor onpatients with burns, multiple trauma, or hantavirus. A Phase II trial ofhead injury patients has also been initiated. Cortech is based in Denver,Colo. _ Philippa Maister
(c) 1997 American Health Consultants. All rights reserved.